drugset / Trial / NCT01214226

Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis

NCT01214226

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The treatment of severe forms of alcoholic hepatitis (AH) constitutes a major challenge for clinicians involved in the management of severe alcoholic liver disease. In patients with Maddrey function higher than 32, compelling evidence from data has shown that corticosteroids improve short-term survival. However, novel strategies or molecules are required in light of the fact that approximately 40 % of patients continue to die at 6 months. A double-blinded randomized controlled trial of 101 patients has showed that Pentoxifylline improves survival of patients with severe AH, as compared to placebo. In terms of mechanisms, the effect of pentoxifylline is related to prevention of hepatorenal function whereas corticosteroids induce an early improvement in liver function. When considering these differences of mechanisms, many clinicians suggest that the addition of pentoxyfilline to corticosteroids is an attractive option that needs to be tested in patients with severe AH.

Timeline

Start
2007-12
Primary completion
2010-12
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pentoxifylline Small molecule 400 mg

Indications